Biochemical recurrence (BCR) after definitive therapy for localized prostate cancer represents an important surrogate end point and heralds metastatic progression and possibly cancer-specific mortality. At 20 yr after radical prostatectomy (RP), as much as 41% of patients demonstrate BCR [1]. Of those with BCR, 10 yr after BCR diagnosis, 25% progress to distant metastases and 11% die of prostat...

BCR/abl is a chimeric oncogene implicated in the pathogenesis of human chronic myelogenous leukemia. Expression of the BCR/abl gene induces hematologic malignancies in transgenic mice and transformation of interleukin-3-dependent hematopoietic cells. The mechanism of BCR/abl-mediated transformation of hematopoietic cells is poorly understood and involves activation of at least two signaling pat...

The chimaeric protein Bcr/Abl, the hallmark of chronic myeloid leukaemia, has been connected with several signalling pathways, such as those involving protein kinase B/Akt, JNK (c-Jun N-terminal kinase) or ERKs (extracellular-signal-regulated kinases) 1 and 2. However, no data about the p38 MAPK (mitogen-activated protein kinase) have been reported. Here, we present evidence showing that Bcr/Ab...

Dendritic arborization is important for neuronal development as well as the formation of neural circuits. Rac1 is a member of the Rho GTPase family that serve as regulators of neuronal development. Breakpoint cluster region protein (BCR) is a Rac1 GTPase-activating protein that is abundantly expressed in the central nervous system. Here, we show that BCR plays a key role in neuronal development...

PURPOSE In the first years of imatinib treatment, BCR-ABL remained detectable in all but a small minority of patients with chronic myeloid leukemia. We determined whether BCR-ABL continues to decline with longer imatinib exposure and the incidence and consequence of undetectable BCR-ABL. EXPERIMENTAL DESIGN BCR-ABL levels were measured in a subset of 53 imatinib-treated IRIS trial patients fo...

Chronic myelogenous leukemia (CML) begins with an indolent chronic phase but inevitably progresses to a fatal blast crisis. Although the Philadelphia chromosome, which generates p210(bcr/abl), is a unique chromosomal abnormality in the chronic phase, additional chromosomal abnormalities are frequently detected in the blast crisis, suggesting that superimposed genetic events are responsible for ...

acute lymphoblastic leukemia(all) is due to early stage arrest of lymphoblast development. the translocation of philadelphia (ph) chromosome occurs as a result of the bcr-abl fusion gene, which constitutively produced activated tyrosine kinase. this gene fusion is an important indicator for prognosis in all and is associated with poor overall survival and remission duration. bcr-abl could inter...

The chimeric Bcr-Abl oncoprotein, which causes chronic myeloid leukemia, mainly localizes in the cytoplasm, and loses its ability to transform cells after moving into the nucleus. Here we report a new strategy to convert Bcr-Abl to be an apoptotic inducer by altering its subcellular localization. We show that a rapalog nuclear transport system (RNTS) containing six nuclear localization signals ...